Annual report
4528.TEDINET S100TMQ7
Period2023-04-01 → 2024-03-31
Filed2024-06-21
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥502.7bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥447.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥361.4bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥309.3bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥292.4bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥159.9bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥142.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥163.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥143.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥105.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥100.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥79.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥128.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥80.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥75.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥59.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥128.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥112.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥913.7bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥882.4bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥739.2bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥745.4bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥673.4bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥115.1bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥134.6bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥798.6bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥747.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥661.7bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥793.0bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥741.9bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥655.9bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥634.1bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥562.5bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥166.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥96.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥69.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥61.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥69.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥110.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥159.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥61.8bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.2bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥48.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥100.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥6.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥57.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥10.2bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥89.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.2bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥24.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥54.7bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥266.61 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥230.85 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥162.19 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥151.11 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥118.47 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥266.57 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥230.79 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥162.16 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥151.09 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥118.45 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,688.43 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,519.19 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,343.4 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,270.45 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,126.95 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 86.8% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 84.1% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 88.7% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 85.1% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 83.5% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 16.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.1% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 3,853 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 3,761 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 3,687 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 3,607 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 3,560 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥498.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥441.2bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥357.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥305.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥286.2bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥187.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥152.0bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥188.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥150.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥121.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥86.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥70.8bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥198.0bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥148.2bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥152.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥117.2bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥94.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥76.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥69.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥847.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥804.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥661.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥669.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥599.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥97.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥119.0bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥750.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥685.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥599.2bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥574.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥507.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥184.8bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥147.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥318.51 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥239.96 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.51 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.1 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.59 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥318.49 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥239.94 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥190.49 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥154.08 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥137.57 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥80 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥56 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,597.16 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,403.84 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,226.79 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,150.68 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,016.83 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 88.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 21.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.2% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 498,692,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 517,425,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,437 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 3,381 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,354 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 3,319 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 3,287 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | employees | at 2024-03-31 | 3853 pure |
| Pharmaceutical Productsreportable segment | employees | at 2024-03-31 | 3437 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,933
| Item | Context | Value | Unit |
|---|---|---|---|
| Software IFRS | CurrentYearInstant | 6883000000 | JPY |
| Other components of intangible assets IFRS | CurrentYearInstant | 659000000 | JPY |
| Intangible assets IFRS | CurrentYearInstant | 57288000000 | JPY |
| Business planning expenses sga IFRS | Prior1YearDuration | 3356000000 | JPY |
| Business planning expenses sga IFRS | CurrentYearDuration | 3694000000 | JPY |
| Sales promotion expenses IFRS | Prior1YearDuration | 17837000000 | JPY |
| Sales promotion expenses IFRS | CurrentYearDuration | 24019000000 | JPY |
| Employee benefit expenses sga IFRS | Prior1YearDuration | 30128000000 | JPY |
| Employee benefit expenses sga IFRS | CurrentYearDuration | 31876000000 | JPY |
| Depreciation and amortization sga IFRS | Prior1YearDuration | 2843000000 | JPY |
| Depreciation and amortization sga IFRS | CurrentYearDuration | 2881000000 | JPY |
| Outsourcing expenses sga IFRS | Prior1YearDuration | 11195000000 | JPY |
| Outsourcing expenses sga IFRS | CurrentYearDuration | 11138000000 | JPY |
| Gain on sale of fixed assets IFRS | Prior1YearDuration | 1000000 | JPY |
| Gain on sale of fixed assets IFRS | CurrentYearDuration | 41000000 | JPY |
| Insurance claim income IFRS | Prior1YearDuration | 284000000 | JPY |
| Insurance claim income IFRS | CurrentYearDuration | 247000000 | JPY |
| Refunded consumption taxes IFRS | Prior1YearDuration | － | JPY |
| Refunded consumption taxes IFRS | CurrentYearDuration | 459000000 | JPY |
| Government grant income IFRS | Prior1YearDuration | 163000000 | JPY |
| Government grant income IFRS | CurrentYearDuration | 142000000 | JPY |
| Other other income IFRS | Prior1YearDuration | 286000000 | JPY |
| Other other income IFRS | CurrentYearDuration | 287000000 | JPY |
| Other income IFRS | Prior1YearDuration | 734000000 | JPY |
| Other income IFRS | CurrentYearDuration | 1176000000 | JPY |
| Impairment losses pl IFRS | Prior1YearDuration | 498000000 | JPY |
| Impairment losses pl IFRS | CurrentYearDuration | 51000000 | JPY |
| Loss on retirement of fixed assets IFRS | Prior1YearDuration | 95000000 | JPY |
| Loss on retirement of fixed assets IFRS | CurrentYearDuration | 159000000 | JPY |
| Donations IFRS | Prior1YearDuration | 2796000000 | JPY |
| Donations IFRS | CurrentYearDuration | 3614000000 | JPY |
| Loss on litigation IFRS | Prior1YearDuration | 7652000000 | JPY |
| Loss on litigation IFRS | CurrentYearDuration | 333000000 | JPY |
| Other other expenses IFRS | Prior1YearDuration | 25000000 | JPY |
| Other other expenses IFRS | CurrentYearDuration | 186000000 | JPY |
| Other expenses IFRS | Prior1YearDuration | 11065000000 | JPY |
| Other expenses IFRS | CurrentYearDuration | 4343000000 | JPY |
| Financial assets measured at amortized cost interest income IFRS | Prior1YearDuration | 70000000 | JPY |
| Financial assets measured at amortized cost interest income IFRS | CurrentYearDuration | 1119000000 | JPY |
| Financial assets measured at fair value through profit or loss interest income IFRS | Prior1YearDuration | － | JPY |
| Financial assets measured at fair value through profit or loss interest income IFRS | CurrentYearDuration | 12000000 | JPY |
| Financial assets measured at fair value through other comprehensive income dividend income IFRS | Prior1YearDuration | 2333000000 | JPY |
| Financial assets measured at fair value through other comprehensive income dividend income IFRS | CurrentYearDuration | 2443000000 | JPY |
| Foreign exchange gain IFRS | Prior1YearDuration | － | JPY |
| Foreign exchange gain IFRS | CurrentYearDuration | 347000000 | JPY |
| Other finance income IFRS | Prior1YearDuration | 76000000 | JPY |
| Other finance income IFRS | CurrentYearDuration | 105000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 2478000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 4027000000 | JPY |
| Financial liabilities measured at amortized cost interest expenses IFRS | Prior1YearDuration | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |